Theravance Biopharma Announces New Employment Inducement

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Theravance Biopharma Announces New Employment Inducement Awards

DUBLIN, IRELAND--(Marketwired - Jan 5, 2016) - Theravance Biopharma, Inc. ( NASDAQ : TBPH ) ("Theravance Biopharma" or the "Company") announced today that stock options to purchase an aggregate of 16,900 of the Company's ordinary shares were granted to four new non-executive officer employees on January 4, 2016. The options were granted in accordance with NASDAQ Listing Rule 5635(c)(4) under the Theravance Biopharma, Inc. 2014 New Employee Equity Incentive Plan (the "Inducement Plan"), which the Board of Directors of Theravance Biopharma adopted in October 2014 to facilitate the granting of equity awards to new employees. Each option has an exercise price per share equal to $16.24, which was the closing price of one Theravance Biopharma ordinary share on the Nasdaq Global Market on the date of grant. The options vest over four years, with 25% of the option shares vesting on the first anniversary of the date of grant and the remaining 75% of the option shares vesting in monthly installments over the three years thereafter. The options have a ten year term, and are subject to the terms and conditions of the Inducement Plan and applicable stock option agreement.

About Theravance Biopharma

The mission of Theravance Biopharma ( NASDAQ : TBPH ) is to create value from a unique and diverse set of assets: an approved product; a development pipeline of late-stage assets; and a productive research platform designed for long-term growth.

Our pipeline of internally discovered product candidates includes potential best-in-class opportunities in underserved markets in the acute care setting, representing multiple opportunities for value creation. VIBATIV ® (telavancin), our first commercial product, is a once-daily dual-mechanism antibiotic approved in the U.S., Europe and certain other countries for certain difficult-to-treat infections. Revenfenacin (TD-4208) is an investigational long-acting muscarinic antagonist (LAMA) being developed as a potential once-daily, nebulized treatment for chronic obstructive pulmonary disease (COPD). Axelopran (TD-1211) is an investigational potential once-daily, oral treatment for opioid-induced constipation (OIC). Our earlier-stage clinical assets represent novel approaches for potentially treating diseases of the lung and gastrointestinal tract and infectious disease. In addition, we have an economic interest in future payments that may be made by Glaxo Group Limited or one of its affiliates ("GSK") pursuant to its agreements with Theravance, Inc. relating to certain drug development programs, including the combination of fluticasone furoate, umeclidinium, and vilanterol (the "Closed Triple").

With our successful drug discovery and development track record, commercial infrastructure, experienced management team and efficient corporate structure, we believe that we are well positioned to create value for our shareholders and make a difference in the lives of patients.

For more information, please visit www.theravance.com .

THERAVANCE ® , the Cross/Star logo, MEDICINES THAT MAKE A DIFFERENCE ® and VIBATIV ® are registered trademarks of the Theravance Biopharma group of companies.

Contact Information: Renee Gala Chief Financial Officer 650-808-4045 investor.relations@theravance.com

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Instanodes Tackling Quantum Threats in Blockchain

Updated Category News Views 0

Diving Into Quantum Cryptography for Blockchain Instanodes is throwing down the gauntlet for the blockchain crowd as the field of quantum computing edges ever closer to unsettling the cryptographic order. This company's latest play? Post-quantum account engineering for major players like Ethereum and Solana. And it's not just tinkering—they're giving the status quo a...

Continue Reading
Envision's Green Ammonia Powers Game-Changing Shipping Milestone

Updated Category News Views 71

Envision's Big Bet on Green Ammonia It's a day to talk about paradigms shifting on the high seas. Envision, a heavy hitter in the green tech arena, just fueled the very first Very Large Ammonia Carrier (VLAC) with their certified green ammonia. Now, that's not just a milestone, it’s like finding a four-leaf clover in the world of maritime decarbonization—a tough nut...

Continue Reading
i-80 Gold's Q3 2026: Production Plans Unveiled

Updated Category News Views 62

Gold Miners on the Move: Eye on i-80 Wake up and smell the gold, folks. i-80 Gold is ramping up to increase its yearly gold production targets, aiming for a hefty 150,000 to 200,000 ounces by 2028. Now, if you’ve been around the block like me, you know these are the kind of numbers that get investors either shifting in their chairs or springing to their feet. A Brief...

Continue Reading
ACA 2027 Enrollment: New Rules Aim to Simplify Coverage

Updated Category News Views 91

Navigating New Waters in 2027 ACA Open Enrollment If you're one of those folks who likes to wait until the last minute, the ACA's got a wake-up call for you this year. The 2027 open enrollment period started on November 1, 2026, with some pretty notable changes. The deadline for coverage beginning January 1, 2027, is December 15, so don't take a nap on this one, alright?...

Continue Reading
HARIBO Unveils Five Boldly Colored Gummies

Updated Category News Views 239

HARIBO's New Fruity Lineup: A Sweet Adventure Hey folks, grab a bag of these new HARIBO gummies, and you're in for a fruity ride. The candy maker's got a new trick up its sleeve with five whimsical, boldly colored gummies. They've dubbed these little treats single-flavor goodies—each with one distinct shape and taste. It's a marketing move that screams 'collect them...

Continue Reading
D-Wave Faces Securities Fraud Class Action: Details Inside

Updated Category News Views 41

D-Wave Quantum Inc. in Hot Water Well folks, looks like D-Wave Quantum Inc. (NASDAQ: QBTS) is knee-deep in a securities fraud class action lawsuit. This ain't just another day in the quantum computing trenches. We've got Kessler Topaz Meltzer & Check, LLP, a big player in securities litigation, rallying the troops here—a clear sign that this case is packing some hefty...

Continue Reading
Oracle's $20 Billion Offering: What Investors Need to Know

Updated Category News Views 97

Oracle's Big Play: A $20 Billion Offering Nobody said playing in the big leagues was easy, and Oracle seems to be doubling down on that idea. Today, they spilled the beans on their ambition to rake in a cool $20 billion through an offering of common stock and senior notes. For those of us who keep a close eye on NYSE:ORCL, this is more than just a number—it's a signal...

Continue Reading
New Study Exposes Grim Reality for Moderate Aortic Stenosis

Updated Category News Views 95

Uncovering the Stark Truth of Moderate Aortic Stenosis When you hear about heart issues, the last thing you want to think about is moderate anything. But this study out of San Diego sure throws a wrench in how we size up moderate aortic stenosis. Turns out these patients aren't just in a holding pattern—they're facing some serious storm clouds. High Stakes for...

Continue Reading
XPENG Eyes South Korea Entry with Industry Veteran

Updated Category News Views 109

A Veteran's Task in a New Territory Piling onto its international ambitions, XPENG has roped in Lee Man-sik, a seasoned auto industry professional, to break into South Korea. South Korea isn’t just another market—it’s one of the toughest stages for the automotive industry. The customers there are sharp, with a keen eye for tech and quality. So XPENG, trading under...

Continue Reading
Andrea P. Davis: A Leadership Luminary Honored

Updated Category News Views 161

A Decade-Spanning Influence in Leadership After years of helping executives navigate the twists and turns of organizational life, Andrea P. Davis stands out as The Inner Circle's Pinnacle Professional of the Year. With over 25 years under her belt, Davis has tackled strategic planning, brand development, and organizational transformation like a prizefighter in the ring....

Continue Reading

Top 5 Most Recently Viewed Articles

Learnologyworld Launches New Domain and Strategic Partnerships

Updated Category News Views 239

Learnologyworld made waves in the online IT training scene by launching its new domain, learnologyworld.net, back in 2024. This wasn't just a simple rebranding; it was a tactical move signaling their expansion and serious commitment to user experience. Traders tuned into this transition because a domain change can often indicate a firm’s strategic pivot—especially in...

Continue Reading
Trump's Advisory Team Proposes Changes to Mining Regulations

Updated Category News Views 181

Trump Administration's Shift on Mining Regulations Advisors to the incoming administration of Donald Trump have put forth significant recommendations regarding mining regulations in the United States. With a focus on enhancing domestic production of critical minerals essential for technologies like electric vehicles and electronics, they propose waiving environmental...

Continue Reading
Vinci Partners to Discuss Strategic Growth in Upcoming Webcast

Updated Category News Views 166

Vinci Partners to Host Virtual Webcast Vinci Partners Investments Ltd. (NASDAQ: VINP) is excited to announce a virtual webcast aimed at exploring the combination with Compass. This event is scheduled for a future date at 8:00 AM ET, where the team will delve into the ongoing integration, synergies, and strategic vision for future growth across Latin America. What to...

Continue Reading
Sale Shifts Gregg Young Chevrolet to New Owners

Updated Category News Views 121

Dealership Transition: A New Chapter in Marshalltown Get this—Gregg Young Chevrolet in Marshalltown, Iowa, is changing hands. This isn't some overnight affair; we're talking about a dealership that's been around and has history in the state. The keys are being passed from the Gregg Young Automotive Group to Alan Reuber and Matthew Barrows, under the stewardship of North...

Continue Reading
Promising Results for Rinatabart Sesutecan in Cancer Trials

Updated Category News Views 229

Rinatabart Sesutecan: A Major Advancement in Cancer Treatment Rinatabart sesutecan (Rina-S) has emerged as a promising option in the battle against ovarian and endometrial cancers. Recent findings from a Phase 1/2 clinical trial emphasize its effectiveness, especially among patients who have already gone through several treatments. This investigational therapy targets...

Continue Reading